Sensitive Subgroup Identification

Sensitive subgroup identification discovers patient populations exhibiting heightened drug susceptibility. Pharmacogenetic testing predicts metabolism phenotypes. Age, renal function, and hepatic status influence sensitivity. Polypharmacy interactions increase sensitivity. Biomarker stratification enables treatment personalisation.

Companion diagnostics identify sensitive populations. Dose adjustment recommendations protect susceptible patients. Regulatory submissions justify subgroup considerations. Clinical outcomes improve with subgroup recognition. Post-approval surveillance detects unexpected subgroup sensitivity.